In a recent article, the overall rates of CNS metastasis were remarkably higher in patients with both BRCA1 and BRCA2 mutations than in noncarriers (BRCA1: 53% and BRCA2: 50% vs. noncarriers: 25%, respectively) [158]. The gene discussed is BRCA2; the disease is metastasis.